While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the hundreds, all the way up to over $1,000 per share or more. At those steep prices, it is difficult to get any decent share count leverage.

Many investors, especially more aggressive traders, look at lower-priced stocks as a way not only to make some good money but to get a higher share count. That can really help the decision-making process, especially when you are on to a winner, as you can always sell half and keep half.

Goldman Sachs is the premier investment bank in the world, so we screened the firm’s outstanding research database and found five stocks trading under the $10 level that could provide investors with some massive upside potential, ranging from over 100% to more than 600%.

While all five are rated Buy at Goldman Sachs, they are much better suited for very aggressive investors, and it is important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.

Array Technologies

This company is still sometimes confused with a biotech with a similar name that Pfizer bought in 2019. Array Technologies Inc. (NASDAQ: ARRY) provides solar tracking solutions and services for utility-scale projects. Its products include DuraTrack HZ v3, a single-axis solar tracking system, and SmarTrack, a machine learning software that automatically adjusts module angles in response to weather and site conditions.

This stock had a red-hot initial public offering in 2020. Shares charged out of the gate, as the first trade was 34% above where the upsized IPO was priced. A total of 47.5 million shares were sold in the offering, as the maker of ground-mounting systems used in solar energy projects sold 7 million shares to raise $154 million and a selling shareholder sold 40.5 million shares.

Since then, Array Technologies stock has crashed and is offering investors an incredible entry point.

Goldman Sachs cut its $24 target price to $20, which compares with the consensus target of $21.80. The shares recently closed at $8.99, so hitting the firm’s target would be a 125% gain.

AvePoint

This is an off-the radar idea with stellar potential. AvePoint Inc. (NASDAQ: AVPT) provides Microsoft 365 data management solutions worldwide. It offers a suite of software as a service solutions to migrate, manage and protect data. The company provides cloud solutions for Office 365, Salesforce and Dynamics 365, as well as hybrid/on-premises products. It also offers advisory and implementation, maintenance and support, Microsoft Teams surge and advisory, migration as a service and quick-start services.
Last year, the company announced the completion of its previously announced business combination with Apex Technology Acquisition Corp., a publicly traded special purpose acquisition company (SPAC).

Goldman Sachs has a $15 price target on AvePoint stock. The consensus target is $13.20 The shares last traded on Friday at $5.74. If the stock hits the firm’s target, investors would have an incredible 150% gain.

Genius Sports

This sports-betting-related stock has been hammered and holds massive upside potential, and it could even be a takeover target. Genius Sports Ltd. (NYSE: GENI) develops and sells technology-led products and services to the sports, sports betting and sports media industries.

It offers technology infrastructure for the collection, integration and distribution of live data of sports leagues; streaming solutions, comprising of technology, automatic production and distribution for sports to commercialize video footage of their games; and end-to-end integrity services to sports leagues, such as full-time active monitoring technology, which uses mathematical algorithms to identify and flag suspicious betting activity in global betting markets, as well as full suite of online and offline educational and consultancy services.

Genius Sports also provides live sports data collection; pre-game and in-game odds feeds; risk management services, including customer profiling, monitoring of incoming bets, automated acceptance and rejection of bets, and limit setting; live streaming services; creation, delivery and measurement services for personalized online marketing campaigns; and fan engagement widgets for digital publishers that offer live game statistics and betting-related content.

The Goldman Sachs price objective of $24 is well above the $17 consensus target. Genius Sports stock closed trading on Friday at $5.30. Hitting the target would be more than a 300% gain.

Kronos Bio

This microcap biotech may be the biggest winner of all the Goldman Sachs Buy-rated stocks under $10. Kronos Bio Inc. (NASDAQ: KRON) a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics.

The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.
The company has planned a registrational Phase 3 clinical trial of entospletinib in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in Phase 1/2 clinical trial.

The $50 Goldman Sachs price target compares with a $40.25 consensus. Both targets indicate plenty of room to run from the recent share closing price of $6.86. In fact, hitting the Goldman Sachs target would be a remarkable 625% gain.

Silverback Therapeutics

This is another microcap biotech that has been hammered but has huge upside to the Goldman Sachs target. Silverback Therapeutics Inc. (NASDAQ: SBTX) is a clinical-stage biopharmaceutical company that develops tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase 1/1b clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric and non-small cell lung cancers.

The company also focuses on developing SBT6290, a product candidate that is in the preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck and non-small cell lung cancers. In addition, it is developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads.

For full disclosure, it should be noted that Silverback has class action suits pending, according to reports. However, that is hardly unusual when clinical trials hit some speed bumps.

Note that the Goldman Sachs price objective of $25 is less than the $36.80 consensus target. However, shares closed trading at $3.88 on Friday, so the Goldman Sachs target represents a gain of over 500%.

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.